Skip to content
Trending storyDeveloping

Quark Pharmaceuticals to Register NorthStar's Actinium-225 in China

3 reports2 sourcesupdated 7 hours ago

Start here

Synthesis

US-based NorthStar Medical Technologies and Quark Pharmaceuticals signed a strategic cooperation agreement on October 14, 2026, under which Quark will serve as NorthStar's registration agent in China for no-carrier-added actinium-225 (n.c.a. Ac-225). Quark will support IND filings by drug developers running clinical studies with NorthStar's isotope. NorthStar is the first company to produce n.c.a. Ac-225 at commercial scale using electron accelerator technology, and the deal aims to expand Chinese developers' access to the radioisotope. Registration work under the arrangement is now proceeding. No terms, timelines, or specific clinical programs covered by the deal have been disclosed.

Written by a model from the reports · updated 2 hours ago

Coverage timeline

Follow the coverage to see the different angles.

Oct 16
  1. mp.weixin.qq.com
    NorthStar Partners with Quark Pharma to Expand Commercial-Scale Ac-225 Access in China

    NorthStar Medical Technologies and Quark Pharma struck a strategic collaboration on October 14, 2026, covering regulatory filings in China for no-carrier-added actinium-225. Quark Pharma will act as NorthStar's registration agent in China, supporting IND filings for drug developers running clinical studies with NorthStar's n.c.a. Ac-225. NorthStar is the first company to produce n.c.a. Ac-225 at commercial scale using electron accelerator technology.

  2. mp.weixin.qq.comPick
    Quark Pharmaceuticals to Serve as NorthStar's China Registration Agent for Actinium-225

    NorthStar Medical Technologies of the US and Quark Pharmaceuticals signed a strategic cooperation agreement on October 14, 2026, covering registration of no-carrier-added actinium-225 (n.c.a. Ac-225) in China. Quark will act as NorthStar's registration agent in China, supporting IND filings for drug developers running clinical studies with NorthStar's n.c.a. Ac-225. Registration work under the arrangement now proceeds.

Heat trend for this story

Heat now 14·Peak in the comparable set 14 (Oct 16 15:00)·Change over 24h in the comparable set –

051015Oct16Oct16Oct16Oct16

The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's heat; the left and right arrow keys work too.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org